Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,077

Document Document Title
WO/2022/115381A1
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein ring D and the substituents are defined herein. Also provided are pharmaceutical compositions comprising a compound of Formula (I) or a p...  
WO/2022/084752A1
The present invention relates to a process for the preparation of 21-(acetyloxy)-17-(1-oxopropoxy)-pregn-4-ene-3,20-dione (VI) having the formula below: Compound (VI) can be used as a precursor for the synthesis of Clascoterone, a steroi...  
WO/2022/078483A1
A quaternary ammonium steroid compound represented by formula I, or an addition salt or a solvate of the quaternary ammonium steroid compound: wherein R 1 is H or CH 3CO; R 2 is CH 3 or -CH 2CH=CH 2, and t is equal to 2 or 3; X is Cl, ...  
WO/2022/040545A1
The invention relates to particular substituted (3α,5β)-3-hydroxy-pregnan-20-ones, in free or pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use ...  
WO/2022/022623A1
The present invention belongs to the technical field of medicine, and particularly relates to an arenobufagin derivative, a preparation method therefor, a pharmaceutical composition thereof, and the use thereof. The arenobufagin derivati...  
WO/2022/022559A1
The present disclosure relates to compounds which exhibit activity in the inhibition of platelet aggregation as well as pharmaceutical compositions comprising these compounds and methods of treatment of vascular diseases by administratio...  
WO/2021/262836A1
Provided herein is a compound of the Formula (I) or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3a, R4a, R4b, R5, R6, R7, R11a, R11b, R15a, R15b, R16,R17, R19, RX, RY, and t are defined herein. Also provided herein are...  
WO/2021/252761A2
Disclosed herein are monomeric and oligomeric compound embodiments for use as contraceptive agents. Monomeric compound embodiments disclosed herein comprise substituents that facilitate the ability of the compounds to exhibit progestogen...  
WO/2021/236953A1
Cationic steroidal antimicrobial (CSA) compounds having a structure of Formula I, II or III, or salt thereof, wherein at least one of R1-R18, (e.g., R18) includes a terpenyl group attached via an ester or amide linkage and at least one R...  
WO/2021/226465A1
The present disclosure relates to polycyclic (e.g., tetracyclic) glucocorticoid receptor (GR) modulators, synthetic methods for preparing such GR modulators, and methods of using such GR modulators to treat a glucocorticoid-dependent con...  
WO/2021/217036A1
A molecule comprising a G-protein coupled estrogen receptor (GPER) ligand coupled to a linker coupled to an E3 ubiquitin ligase ligand and methods of using the molecule are provided. In one embodiment, the GPER ligand is estradiol and th...  
WO/2021/188778A2
Provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R 4a, R4b, R5, R6a, R6b, R11a, R11b, R15a, R15b, R16a, R16b, R18, R19, R20a, R20b, X, A, Z, q, u, r, s, t, m, and n are de...  
WO/2021/179512A1
The present invention "an anti-influenza virus compound, and a preparation method therefor and an application thereof" relates to the technical field of pharmaceutical chemistry. The anti-influenza virus compound has the following struct...  
WO/2021/147123A1
The present invention provides a compound having antisporulant activity and a pharmaceutical composition thereof, and specifically provides a compound represented by formula (I), or a salt thereof, or a stereoisomer thereof. The compound...  
WO/2020/147852A9
The present application relates to crystal form 04, crystal form 06, crystal form D-1, and crystal form D-2 of an antidepressant drug SAGE-217 and a preparation method therefor and a pharmaceutical composition containing same. The XRPD o...  
WO/2021/145785A1
Proposed are different benzimidazole derivatives based on thermolabile compounds, for example amino acids and vitamins, which exhibit geroprotective activity in trials and can be used for developing agents for prolonging life in humans a...  
WO/2021/126281A1
Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit t...  
WO/2021/113068A1
The invention provides novel neuroactive steroids and pharmaceutical compositions thereof, as well as methods of their preparation and use, in therapy of various diseases and conditions, for example, various neurological or brain diseases.  
WO/2021/100019A1
The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers, or pharmaceutically acceptable salt(s) thereof as prodrugs of abiraterone. The present invention also describes method of makin...  
WO/2021/096542A1
Formulated and/or co-formulated liposomes comprising IDO prodrugs and methods of making the liposomes are disclosed herein. The IDO prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit IDO-1. The IDO...  
WO/2021/097046A1
The disclosure relates to anti-cancer compounds which are anti-cancer PARP inhibitors of formula Al, A2, A3 or A4 conjugated by a linker to a steroid, whereby the steroid targets the conjugate to the nucleus, as well as to methods for th...  
WO/2021/082882A1
Disclosed is a method for anchoring and modifying a nano-drug on the surface of a living cell. The method comprises: introducing an active reaction group to the surface of a living cell by means of a hydrophobic tail chain of a cell memb...  
WO/2021/080880A1
N-methyl-d-aspartate receptors (NMDAR) and/or potentiating y-aminobutyric acid receptors (GABAAR) agents and uses thereof are described. Uses of these agents include methods of treating or preventing various psychiatric diseases, disorde...  
WO/2021/069570A1
Compounds and compositions for the activation of SERCA2a are disclosed. In particular, provided are compounds that act as predominantly pure or pure SERCA2a activators while only moderately inhibiting the Na+/K+ ATPase. In general, the d...  
WO/2021/041896A1
The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel radiohalogenated (e.g., radioiodinated) PSMA targeting agents and ...  
WO/2021/027306A1
Disclosed is a conjugate obtained by condensing dihydroartemisinin and a steroid, as represented by the following general formula (I), or an isomer, pharmaceutically acceptable salt, or prodrug molecule thereof; wherein the hydroxy group...  
WO/2021/023213A1
The present invention relates to a steroid derivative regulator, in particular to a compound of formula (I), a salt and crystal form thereof, a preparation method therefor, a pharmaceutical composition containing a therapeutically effect...  
WO/2020/259612A1
Disclosed in the present invention are a compound represented by general formula I, a pharmaceutically acceptable salt, solvate, or stereoisomeride containing mixtures at different ratios thereof, and a pharmaceutical composition contain...  
WO/2020/264512A1
Provided herein in part is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of Formula I, and methods of using the compounds, e.g, in the treatment of CNS- relate...  
WO/2020/264495A1
Provided herein is a compound of Formula (1-I): or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R11a, R11b, R16a, R16b, R19, R18, X, q, r, s, t, u, and n are defined herein. Also provided here...  
WO/2020/242772A1
The present disclosure encompasses solid state forms of SAGE-217, in embodiments SAGE-217: Oxalic acid Co-crystal, processes for preparation thereof, and pharmaceutical compositions thereof.  
WO/2020/243488A1
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7a, R7a, R11a, R11b, R12a, R12b, R16a, R16b, R19, R11a, R22, RX, RY and n are defined he...  
WO/2020/210116A1
The invention provides steroid compounds with altered pharmacological properties and methods of using the compounds to treat a condition in a subject.  
WO/2020/200335A1
The invention provides 3α5β–steroid compounds of general formula I. These compounds are useful in the treatment of epilepsy or comorbidities associated with epilepsy or conditions associated with convulsions, such as seizures associa...  
WO/2020/180942A1
Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, a syndrome due to androgen excess, and/...  
WO/2020/172655A1
Provided are compounds, which may be referred to as PHOTACs (photoswitchable proteolysis targeting chimeras), and compositions, kits, and methods of making and using PHOTACs. PHOTACs have one or more E3 ligase ligand(s), one or more phot...  
WO/2020/163026A1
Unusual and unexpectedly stable aqueous suspension formulation and water dispersible dry composition of the following formula (I) compounds. It causes little or no injection site irritation and has superior properties over non-aqueous fo...  
WO/2020/146541A2
Provided herein are compounds, compounds including traceless linkers, protein conjugates thereof, and compositions thereof. Also provided herein are methods for the treatment of diseases, disorders, and conditions, and/or the management ...  
WO/2020/135454A1
Provided in the present invention are compounds of formulae (I), (II), (III) and (IV), a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. Disclosed are a method for preparing such compounds and the use of the compo...  
WO/2020/132504A1
Provided herein is a compound of Formula (I) or pharmaceutically acceptable salt thereof, wherein R2a, R2b, R4a, R4b, R6, R7, R11a, R11b, R16, R17, R3, R5, R19 and RX are defined herein and wherein RY represents optionally substituted he...  
WO/2020/128514A1
2-Fluorinated bile acid compounds of general formula (I) wherein at least one of R1 and R2 represents F and the other is chosen 3 from H and F and wherein R3 is as defined herein; are of use in the treatment and prevention of neurodegene...  
WO/2020/131918A1
The invention relates to particular prodrugs and analogs of (3α,5α)-3-hydroxy-21-(1H-imidazol-1-yl)-3-methoxymethyl)-p regnan-20-one, in free or pharmaceutically acceptable salt and/or substantially pure form as described herein, pharm...  
WO/2020/124094A1
The invention relates to methods of treating depression with Compound 1 or pharmaceutically acceptable salts thereof. The present disclosure, among other things, provides methods of treating depression by administering a therapeutically ...  
WO/2020/115371A1
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof (I) wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or ...  
WO/2020/118060A1
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2 a, R2 b, R4 a, R4 b, R6a, R6b, R7a,R7b,R11a, R11b, R12a,R12b, R18, RD, and q are defined herein. L is selected...  
WO/2020/082065A1
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein n, R19, R5, R3, R6a, R6b, R2a, R2b, R4a, R4b, R7a, R7b, R11, R12a, R12b, R16, R21a, R21b, and R21c are defined herein. Also provided here...  
WO/2020/077255A1
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein n, R19, R5, R3a, R6a, R6b, R1, R2a, R2b, R4a, R4b, R7a, R7b, R11a, R11b, R12a, R12b, R17b, R15a, R15b, R16a and R16b are defined herein. ...  
WO/2020/020728A1
Disclosed are compounds of formula (I), wherein X, Y, Z are annular atoms comprised in a five-membered carbocyclic or heterocyclic ring, selected from the group consisting of CH, NH, N, O, S; saidcarbocyclic or heterocyclic ring being op...  
WO/2020/018893A1
Compounds of formula: are described herein. The compounds selectively complex copper and are therefore useful both abiotically for measuring and detecting small amounts of copper and, in biological systems, for treating diseases associat...  
WO/2020/015659A1
Provided is a method for refining crude rocuronium bromide; the method comprises: using vacuum microwave drying or fluidized drying to remove residual solvent in crude rocuronium such that same meets medicinal requirements. Using the met...  

Matches 1 - 50 out of 1,077